Revolution Medicines (NASDAQ:RVMD) Director Lorence Kim Sells 17,090 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) Director Lorence Kim sold 17,090 shares of Revolution Medicines stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $209.82, for a total transaction of $3,585,823.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Revolution Medicines Trading Down 2.1%

Shares of NASDAQ:RVMD opened at $203.35 on Friday. The company’s 50-day moving average price is $198.37 and its two-hundred day moving average price is $155.89. Revolution Medicines, Inc. has a one year low of $42.18 and a one year high of $224.31. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The stock has a market capitalization of $43.59 billion, a PE ratio of -23.06 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the company posted ($1.31) earnings per share. On average, equities analysts forecast that Revolution Medicines, Inc. will post -8.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RVMD has been the subject of a number of analyst reports. Oppenheimer raised their price target on Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. TD Cowen raised Revolution Medicines to a “strong-buy” rating in a report on Monday, August 24th. Guggenheim raised their target price on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Friday, August 28th. Royal Bank Of Canada raised their target price on shares of Revolution Medicines from $203.00 to $251.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Finally, Wolfe Research restated an “outperform” rating and set a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $218.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sequoia Financial Advisors LLC acquired a new position in shares of Revolution Medicines during the 2nd quarter worth approximately $626,000. MCF Advisors LLC bought a new position in Revolution Medicines during the second quarter worth $78,000. National Pension Service bought a new position in Revolution Medicines during the second quarter worth $51,241,000. Engineers Gate Manager LP increased its holdings in shares of Revolution Medicines by 144.0% in the second quarter. Engineers Gate Manager LP now owns 7,380 shares of the company’s stock valued at $1,382,000 after purchasing an additional 4,356 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Revolution Medicines in the second quarter valued at $278,000. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.